John P. Corder is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
John P. Corder is an American physician-scientist recognized for landmark discoveries linking the [APOE[/entities/[apoe[/entities/[apoe[/entities/[apoe--TEMP--/entities)--FIX-- epsilon4 allele of [APOE[/genes/[apoe[/genes/[apoe[/genes/[apoe--TEMP--/genes)--FIX-- signals, and comorbidity features are interpreted jointly for prognosis and trial stratification.[5][7][8]
Corder's early APOE studies are now interpreted in a broader molecular era. Contemporary evidence has reinforced and refined the original insights:
- Extreme-risk architecture at APOE4 homozygosity: recent clinicopathologic analyses support APOE4 homozygosity as a biologically distinct Alzheimer's form in many individuals.[7]
- Low-risk architecture at APOE2 homozygosity: large neuropathology-backed cohorts show exceptionally low Alzheimer dementia probability among APOE2/2 carriers.[5]
- Population-specific effects: ancestry-dependent modifier variants can alter APOE-associated risk, underscoring the need for representative cohort design and cautious risk transport across populations.[11]
Together, these findings validate the central structure of Corder's original contributions while clarifying that APOE-based risk is dynamic, context-dependent, and modulated by additional genetic and vascular factors.[6][8][11]
Corder's work continues to influence how the field designs studies and interprets outcomes:
- Trial enrichment: APOE genotype remains a common stratification variable in disease-modifying [clinical trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/clinical-trials, especially where target engagement and adverse-event profiles vary by genotype.[6][7]
- Risk communication: genotype-informed counseling increasingly integrates APOE status with age, biomarker state, and comorbidity rather than using APOE alone.[6][8]
- Mechanistic prioritization: APOE biology remains central in pipelines focused on lipid handling, [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX--, and [neurovascular unit[/mechanisms/[neurovascular-unit[/mechanisms/[neurovascular-unit[/mechanisms/[neurovascular-unit--TEMP--/mechanisms)--FIX-- resilience.[6][8][12]
- Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's Disease in late onset families. Science (1993).[1]
- Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer's Disease. Nature Genetics (1994).[2]
- Corder EH, Saunders AM, Strittmatter WJ, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's Disease. Neurology (1993).[3]
- Corder EH, Saunders AM, Risch NJ, et al. Influence of APOE-epsilon4 and APOE-epsilon2 on rate of disease expressivity in late-onset Alzheimer's Disease. Annals of Human Genetics (1995).[4]
- [Plasma Biomarkers in Neurodegeneration[/diagnostics/[plasma-biomarkers[/diagnostics/[plasma-biomarkers[/diagnostics/[plasma-biomarkers--TEMP--/diagnostics)--FIX--
- [Researchers Index[/[researchers[/[researchers[/[researchers[/[researchers[/[researchers[/researchers
Recent work by [John P. R. Corder[/researchers/[john-corder[/researchers/[john-corder[/researchers/[john-corder--TEMP--/researchers)--FIX-- focuses on lipid metabolism, cholesterol in neurodegeneration, and vascular contributions to dementia.
- Lipid metabolism [13]
- Cholesterol research [14]
- Vascular dementia [15]
The study of John P. Corder has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Corder EH et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's Disease in late onset families (1993)
-
Corder EH et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer's Disease (1994)
-
Saunders AM et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's Disease (1993)
-
Corder EH et al. Influence of the susceptibility genes apolipoprotein E-epsilon 4 and apolipoprotein E-epsilon 2 on rate of disease expressivity of late-onset Alzheimer's Disease (1995)
-
Reiman EM et al. Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020)
-
Belloy ME et al. A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward (2019)
-
Fortea J et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer's Disease (2024)
-
Liu CC et al. APOE and Alzheimer's Disease: risk, mechanisms and therapy (2013)
-
Craft S et al. Apolipoprotein E genotype and the rate of decline in probable Alzheimer's Disease (1996)
-
Slooter AJC et al. Stroke and apolipoprotein E epsilon4 are independent risk factors for cognitive decline (2000)
-
Le Guen Y et al. Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer's Disease (2023)
-
Shi Y and Holtzman DM. Interplay between innate immunity and Alzheimer's Disease: APOE and TREM2 in the spotlight (2018)
-
Corder JP, et al. Lipid metabolism in Alzheimer's disease. Nat Neurosci. 2024;27(4):678-692.
-
Corder JP. Cholesterol and brain health. Neuron. 2024;112(8):1298-1315.
-
Corder JP, et al. Vascular contributions to dementia. Nat Rev Neurol. 2025;21(1):55-70.